Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Recommendation of "Buy" from Analysts

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) has received an average recommendation of "Buy" from the eight research firms that are covering the company, MarketBeat reports. Seven investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $13.39.

VYGR has been the subject of a number of research reports. Wedbush reaffirmed an "outperform" rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. Wells Fargo & Company set a $10.00 price objective on Voyager Therapeutics and gave the company an "overweight" rating in a research note on Wednesday, March 12th. Canaccord Genuity Group decreased their price objective on Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating for the company in a research report on Thursday, March 13th. HC Wainwright restated a "buy" rating and set a $30.00 price target on shares of Voyager Therapeutics in a research note on Tuesday, April 8th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th.

Institutional Trading of Voyager Therapeutics

A number of institutional investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC acquired a new stake in Voyager Therapeutics in the fourth quarter valued at $29,000. Tower Research Capital LLC TRC increased its holdings in shares of Voyager Therapeutics by 133.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company's stock valued at $31,000 after purchasing an additional 3,077 shares in the last quarter. Picton Mahoney Asset Management lifted its stake in shares of Voyager Therapeutics by 71.1% in the fourth quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company's stock valued at $33,000 after purchasing an additional 2,444 shares during the period. CWM LLC boosted its holdings in Voyager Therapeutics by 856.3% during the first quarter. CWM LLC now owns 10,471 shares of the company's stock worth $35,000 after buying an additional 9,376 shares in the last quarter. Finally, Oxford Asset Management LLP purchased a new stake in Voyager Therapeutics during the fourth quarter worth about $60,000. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

Voyager Therapeutics Trading Up 4.6%

Shares of Voyager Therapeutics stock traded up $0.14 on Friday, hitting $3.18. The stock had a trading volume of 352,932 shares, compared to its average volume of 481,191. The company's 50 day moving average price is $3.20 and its 200 day moving average price is $4.00. The stock has a market cap of $175.98 million, a price-to-earnings ratio of -2.18 and a beta of 0.85. Voyager Therapeutics has a 52-week low of $2.65 and a 52-week high of $9.55.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.18). The firm had revenue of $6.47 million during the quarter, compared to analysts' expectations of $13.55 million. Voyager Therapeutics had a negative net margin of 126.49% and a negative return on equity of 27.36%. Analysts predict that Voyager Therapeutics will post -0.91 EPS for the current fiscal year.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.